Sarepta Theraps Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SAREPTA THERAPS INC, and what generic alternatives to SAREPTA THERAPS INC drugs are available?
SAREPTA THERAPS INC has three approved drugs.
There are twenty-three US patents protecting SAREPTA THERAPS INC drugs.
There are one hundred and sixty-three patent family members on SAREPTA THERAPS INC drugs in twenty-six countries.
Summary for Sarepta Theraps Inc
International Patents: | 163 |
US Patents: | 23 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 3 |
Drugs and US Patents for Sarepta Theraps Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 9,243,245 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 10,364,431 | ⤷ Sign Up | ⤷ Sign Up | ||||
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | RX | Yes | Yes | 9,243,245 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | RX | Yes | Yes | 10,337,003 | ⤷ Sign Up | ⤷ Sign Up | ||||
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 10,337,003 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sarepta Theraps Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | 10,533,174 | ⤷ Sign Up |
Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | 10,533,174 | ⤷ Sign Up |
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | 9,416,361 | ⤷ Sign Up |
Sarepta Theraps Inc | VYONDYS 53 | golodirsen | SOLUTION;INTRAVENOUS | 211970-001 | Dec 12, 2019 | 9,416,361 | ⤷ Sign Up |
Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | 10,533,174 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Sarepta Theraps Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2704049 | ⤷ Sign Up |
Poland | 2499249 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2010050802 | ⤷ Sign Up |
Brazil | 122023023194 | ⤷ Sign Up |
China | 105641700 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.